stockrow
Saturday 7 November 2026
Export ANRO’s income statement to Excel — free account
Alto Neuroscience, Inc.
ANRO Healthcare Biotechnology
- EPS
- 0.00%
- Free cash flow
- −43.4%
- Total debt
- −15.7%
Quarter to June 2026, against a year earlier
25.16
3.29
+15.04%
Follow ANRO
Alert me
Alto Neuroscience, Inc. (ANRO) P/E ratio
Alto Neuroscience, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2021 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GLUE Monte Rosa Therapeutics, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. | n/m |
| ORIC Oric Pharmaceuticals, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | n/m |
| SNDX Syndax Pharmaceuticals, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.4× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 34.2× |
| LTGO Latigo Biotherapeutics Inc compare | — |
| CTY City Therapeutics, Inc compare | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)